A statement read: “The Danish Health Authority concluded that the benefits of using the Johnson & Johnson COVID-19 vaccine do not outweigh the risk of causing a possible side effect, VITT, in those who receive the vaccine. Therefore, the Health Authority will continue the Danish COVID-19 mass vaccination program without the COVID-19 vaccine from Johnson & Johnson. “
The decision was not an easy one, she stressed, especially after she also ditched AstraZeneca’s vaccine.
“Given the current situation in Denmark, what we are currently losing in our efforts to prevent serious illness from COVID-19 cannot outweigh the risk of causing possible side effects in the form of serious blood clots in people we vaccinate, ”the statement said. continued.
He added that the decision “will significantly affect” the roll-out of the vaccination for people aged 20 to 39, which will be delayed for up to four weeks.
“The remaining target groups will experience a delay of about a week, as we will receive large amounts of other vaccines,” he continued.
“This decision will, of course, have consequences for those who are now seeing their vaccination postponed. For example, they will have to wait longer for the corona passport than many of us look forward to. Age is the main risk factor for serious illness from COVID-19, and it is younger citizens who are not at risk of becoming seriously ill, ”he said.
As of May 1, more than 1.3 million of the country’s 5.8 million people had received at least one dose of the vaccine, according to Our World in Data.
The Johnson & Johnson vaccine – also known as Janssen – in March became the fourth vaccine to be approved for use in the European Union by the European Medicines Agency (EMA) after Pfizer / BioNTech, AstraZeneca / Oxford University and Moderna.
But the US pharmaceutical has delayed deliveries to the 27-member bloc after reports of serious blood clots emerged in the United States where more than 6.8 million people have received at least one vaccine.
the The EMA has launched a review last month, but said he remained of the view that “the vaccine’s benefits in preventing COVID-19 outweigh the risks of side effects.”
He voiced a similar view of the AstraZeneca vaccine after investigating reports of blood clots. Yet several member states, including Denmark and Norway, have withdrawn the Anglo-Swedish vaccine from their deployments.
Other Member States have limited the use of the AstraZeneca vaccine to older age groups, who have been found to be less likely to develop blood clots. French authorities have already announced that they plan to carry out the Janssen vaccine for people aged 55 and over.
So far, EU countries have received just over a million doses of the vaccine, according to the European Center for Disease Prevention and Control.